British Startup Launches Orbiting Lab to Study Disease Proteins
.png)
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Mass Balance launched a grapefruit-sized autonomous lab on a SpaceX transporter Tuesday morning, with chemicals, sensors, and control elements that will run self-directed experiments in orbit for several months.
- The experiment sits inside a 10-centimeter pod built by Austrian firm Tumbleweed, automatically beaming back data on how live cells grow and react under weak gravity.
- Co-founder and CEO Toby Call said the platform targets disordered proteins linked to Alzheimer's, Parkinson's, and certain cancers — molecules that constantly shift shape on Earth, where convection and sedimentation distort measurements.
- Call plans to feed microgravity-collected data into an AI model adapter that fills gaps left by Google's AlphaFold, with revenue coming from the model itself, data licensing, and data access.
- This first mission only validates the operating system and data pipeline: it sends an industrial biocatalyst to break down a chemical compound, monitored via light to confirm the reaction proceeds as designed.
- Unlike BioOrbit (growing cancer-drug crystals in orbit) and Varda Space Industries (processing pharmaceuticals under microgravity), Mass Balance will not attempt to return its hardware to Earth, sidestepping the heat and stress of atmospheric re-entry.
Why it matters: Mass Balance's 'leave it in orbit' approach avoids the re-entry engineering that trips up BioOrbit and Varda — if its autonomous data pipeline proves out, the company gets a cheaper path to training AI on proteins behind Alzheimer's and Parkinson's, filling a dataset gap AlphaFold explicitly cannot close on Earth.
